Klinicka Onkologie最新文献

{"title":"Analysis of progression of number and structure of scans performed using PET, PET/ CT and PET/ MRI in the Czech Republic in 2013- 2021.","authors":"J Adam, A Svobodník, R Štěpánová, D Zogala, M Havel, T Büchler, M Svoboda","doi":"10.48095/ccko2024259","DOIUrl":"10.48095/ccko2024259","url":null,"abstract":"<p><strong>Background: </strong>Positron emission tomography (PET) is a state-of-the-art diagnostic method of nuclear medicine, used for diagnostics of many pathological states in the organism, first and foremost in oncological issues. The first analysis of utilization and potential utilization of PET in the Czech Republic was published in 2013. In the following years, there was a sharp increase in a number of PET/CT and PET/MRI scanners in the country; in 2013-2021, it doubled. Simultaneously with the increase in scans performed, the range of available radiopharmaceuticals also broadened.</p><p><strong>Material and methods: </strong>The study analyses the numbers and structure of PET, PET/CT and PET/MRI scans in the 2013-2021 period, using the pseudonymized data acquired from the General Health Insurance Company of the Czech Republic. The data was evaluated through a series of qualitative and quantitative indicators (number of scans performed, structure of diagnoses, use of different tracers, and availability of a scan for a patient).</p><p><strong>Results: </strong>In the observed interval of time, the number of scans performed practically doubled, both thanks to more scanners installed and more radiopharmaceuticals available. The percentage of oncological and non-oncological scans remains more or less the same. Nevertheless, the regional differences in a number of scans performed persist, as does the availability of the scan for patients.</p><p><strong>Conclusion: </strong>PET is still a dynamically developing molecular imaging method in the Czech Republic. The analysis of a number and structure of scans performed offers a priceless overview of the development of the method over the years, in regard to diagnoses, utilization of individual radiopharmaceuticals or geographic distribution of scans performed. The observed findings are a motivation for further analyses.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":"38 4","pages":"259-269"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gemcitabine/nab-paclitaxel in first line treatment of advanced pancreatic cancer - head-to-head comparison with the mFOLFIRINOX regimen.","authors":"J Tomášek","doi":"10.48095/ccko2024331","DOIUrl":"10.48095/ccko2024331","url":null,"abstract":"<p><strong>Background: </strong>Metastatic pancreatic ductal carcinoma (mPDAC) is one of the most lethal malignancies. The European Society for Medical Oncology (ESMO) guidelines recommend a gemcitabine doublet + nab-paclitaxel (Gem/Nab-P) or a modified FOLFIRINOX regimen (mFOLFIRINOX) as options for systemic chemotherapy. Gemcitabine monotherapy is an option for patients in a worse performance status (PS). Indirect comparisons of pivotal trials with Gem/Nab-P and mFOLFIRINOX vs. gemcitabine monotherapy (PRODIGE-4 and MPACT) indicated longer overall survival (OS) in patients treated with mFOLFIRINOX. However, it should be taken into account that the MPACT study with Gem/Nab-P included patients with an overall worse performance status. A direct comparison of these chemotherapy regimens was lacking. Indirect comparisons from real practice show their comparable effectiveness in terms of OS, progression-free survival and overall response rate. The safety profile is consistently different. The recently published phase II/III GENERATE trial, which directly compared Gem/Nab-P and mFOLFIRINOX in treatment-naïve mPDAC patients, demonstrated significantly longer OS in Gem/Nab-P-treated patients exceeding 17 months with a lower incidence of non-hematologic toxicity. The results sparked a lively discussion at the ESMO 2023 Congress. The comparison of Gem/Nab-P and mFOLFIRINOX was also addressed by prof. Prager in his presentation at the PragueONCO 2024 conference. Prager, who highlighted comparable efficacy of both regimens and better safety of Gem/Nab-P and demonstrated the benefit of Gem/Nab-P also in patients older than 70 years and those with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2. It should also be taken into account that the choice of first line treatment determines the therapeutic options in the 2nd line. If the Gem/Nab-P regimen is used in the first line, pegylated liposomal irinotecan (nal-IRI) in combination with 5-fluorouracil and leucovorin (5-FU/LV) can be used in the second line. This regimen demonstrated prolongation of OS compared to 5-FU/LV in phase III study NAPOLI-1. In patients pretreated with the mFOLFIRINOX regimen, gemcitabine monotherapy or Gem/Nab-P can be used in the second line. Early examination of molecular predictive parameters will enable the identification of cases for which appropriate targeted therapy or immunotherapy is available.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":"38 5","pages":"331-334"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142629077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An atypical presentation of bronchogenic cyst.","authors":"H Matsumoto, S Hasegawa, Y Maezawa, S Okauchi, G Ohara, K Iguchi, H Kawai, N Takayashiki, H Satoh","doi":"10.48095/ccko2024463","DOIUrl":"10.48095/ccko2024463","url":null,"abstract":"<p><strong>Background: </strong>Bronchial cysts (BCs) can be difficult to diagnose because of non-specific site of occurrence and heterogeneous density of cyst content in some patients. We present herein a BC case with such nonspecific findings.</p><p><strong>Case: </strong>A 23-year-old man referred to our hospital because of an abnormal chest image during a mass-screening. CT revealed a cystic nodule in the posterior mediastinum. The content of the cystic lesion was heterogeneous, measuring 30-100 Hounsfield Units, and it was surgically resected and diagnosed as a BC.</p><p><strong>Conclusion: </strong>Diagnosis of BC could be difficult in patients like this, who have cysts that occur in relatively rare sites such as the posterior mediastinum, or whose cyst contents are highly dense and heterogenous. If atypical findings are observed on images, it is necessary to actively perform histological diagnosis to differentiate it from other diseases.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":"39 6","pages":"463-466"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142956107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autoimmune pancreatitis as a risk factor of pancreatic cancer.","authors":"D Solil, P Dítě, B Kianička, M Bojková, M Uvírová, M Přecechtělová, J Dolina","doi":"10.48095/ccko2024420","DOIUrl":"10.48095/ccko2024420","url":null,"abstract":"<p><strong>Background: </strong>Autoimmune pancreatitis (AIP) is a form of chronic pancreatitis that presents clinically with obstructive icterus, histologically with infiltration of pancreatic parenchyma by inflammatory cells leading to chronic inflammation with fibrosis, and therapeutically with good response to corticosteroid therapy. Clinically, it may resemble malignant disease, making diagnosis difficult and requiring a multidisciplinary team (gastroenterologist, endoscopist, radiologist, surgeon, pathologist). Two types of AIP are distinguished. Type 1 is associated with elevated serum immunoglobulin IgG4 and systemic manifestations (IgG4 related diseases). Type 2, without IgG4 elevation, is typically associated with the occurrence of idiopathic inflammatory bowel disease, especially ulcerative colitis. The first line treatment of symptomatic AIP is corticotherapy with an initial dose of 0.6-1 mg/kg/day for the first 2-4 weeks, followed by a gradual de-escalation to prevent frequent relapses. Chronic inflammation, or chronic pancreatitis, is a well-known risk factor for the development of malignancy. The association between carcinogenesis and AIP is widely discussed, but due to the rarity of the disease and a small number of studies, risk estimates vary. Pancreatic carcinoma development is most common in patients with type 1 autoimmune pancreatitis. However, it has been observed that the incidence of extra-pancreatic cancer (stomach, lung, and prostate cancer) is often equal or even higher. It is also considered that AIP may develop from coexisting malignancies as a paraneoplastic syndrome. Screening of patients with AIP for potential carcinogenesis should not be overlooked.</p><p><strong>Purpose: </strong>The aim of this review article is to point out a rare (autoimmune) form of chronic pancreatitis with the necessity of follow up with regard to the potential risk of malignancy.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":"39 6","pages":"420-426"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142956108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic diagnostics of familial hematopoietic disorders","authors":"Zuzana Vrzalová, Lenka Radová, Kateřina Staňo Kozubík, Jiří Štika, Jakub Trizuljak, Šárka Pospíšilová, Michael Doubek","doi":"10.48095/ccko2023s131","DOIUrl":"https://doi.org/10.48095/ccko2023s131","url":null,"abstract":"","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":"19 8","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136067547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EHealth support for mental health of oncology patients – is there patient interest? Summary of the first year with the MOÚ MindCare mobile application","authors":"Zdeňka Barešová, Miroslav Světlák, Dana Vigašová, Jana Halámková, Jiří Šedo","doi":"10.48095/ccko2023s119","DOIUrl":"https://doi.org/10.48095/ccko2023s119","url":null,"abstract":"","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":"36 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136067770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular pharmacotherapy in patients with triple negative breast cancer before and after anthracycline treatment","authors":"Anna Bartáková, Ivana Koloušková, Miloš Holánek, Iveta Selingerová, Tibor Stračina, Tomáš Kazda, Marie Nováková","doi":"10.48095/ccko2023s123","DOIUrl":"https://doi.org/10.48095/ccko2023s123","url":null,"abstract":"","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":"160 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136068578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of Schlafen 11 as a predictive biomarker in ovarian cancer patients treated with platinum-based chemotherapy – results of the pilot analysis","authors":"Jitka Hausnerová, Lucie Ehrlichová, Petra Ovesná, Květoslava Matulová, Janka Chlubnová, Vít Weinberger, Markéta Bednaříková","doi":"10.48095/ccko2023s127","DOIUrl":"https://doi.org/10.48095/ccko2023s127","url":null,"abstract":"","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":"95 7","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136104641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study of KDM1A and VEGF changes as the responsible genes in the angiogenesis of breast cancer","authors":"Niloufaralsadat Hashemi, M. Kavousi, Faranak Jamshidian","doi":"10.48095/ccko2023281","DOIUrl":"https://doi.org/10.48095/ccko2023281","url":null,"abstract":"","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41521079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How patients can help us be even better doctors – educational leaflet “Before I go to the doctor”","authors":"M. Svetlak, Vladimíra Šnajdrová, Klára Fialová","doi":"10.48095/ccko2023307","DOIUrl":"https://doi.org/10.48095/ccko2023307","url":null,"abstract":"","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47743716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}